Europe Kidney Cancer Therapeutics and Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

1. INTRODUCTION

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Number of Kidney Cancer Cases
  • 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
• 4.3 Market Restraints
  • 4.3.1 High Cost Associated with Treatment
  • 4.3.2 Preference for Generic Drugs
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

• 5.1 By Cancer Type
  • 5.1.1 Clear cell RCC
  • 5.1.2 Papillary RCC
  • 5.1.3 Chromophobe RCC
  • 5.1.4 Urothelial carcinoma/Transitional cell carcinoma
  • 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
• 5.2 By Component
  • 5.2.1 Drugs
  • 5.2.1.1 Therapeutic Class
  • 5.2.1.1.1 Targeted Therapy
  • 5.2.1.1.2 Immunotherapy
  • 5.2.1.1.3 Other Therapeutic Class
  • 5.2.1.2 By Pharmacologic Class
  • 5.2.1.2.1 Angiogenesis Inhibitors
  • 5.2.1.2.2 Monoclonal Antibodies
  • 5.2.1.2.3 mTOR Inhibitors
  • 5.2.1.2.4 Cytokine Immunotherapy (IL-2)
  • 5.2.2 Diagnostics
  • 5.2.2.1 Biopsy
  • 5.2.2.2 Imaging Tests
  • 5.2.2.3 Blood Tests
  • 5.2.2.4 Other Diagnostics
• 5.3 Geography
  • 5.3.1 Europe
  • 5.3.1.1 Germany
  • 5.3.1.2 United Kingdom
  • 5.3.1.3 France
  • 5.3.1.4 Italy
  • 5.3.1.5 Spain
  • 5.3.1.6 Rest of Europe

6. COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Pfizer Inc
  • 6.1.2 F. Hoffmann-La Roche Ltd
  • 6.1.3 Bayer AG
  • 6.1.4 Novartis AG
  • 6.1.5 Amgen Inc
  • 6.1.6 Abbott Laboratories
  • 6.1.7 Cerulean Pharma Inc
  • 6.1.8 Eisai co Ltd
  • 6.1.9 Seattle Genetic
  • 6.1.10 BRISTOL-MYERS SQUIBB COMPANY
• *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS